Evaluation of the relationship between serum irisin levels and disease activity in ankylosing spondylitis patients
Original Article
P: 1-6
March 2024

Evaluation of the relationship between serum irisin levels and disease activity in ankylosing spondylitis patients

J Turk Soc Rheumatol 2024;16(1):1-6
1. İzmir Katip Çelebi Üniversitesi, Atatürk Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Romatoloji Bölümü, İzmir, Türkiye
2. Sağlık Bilimleri Üniversitesi, Tepecik Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Hematoloji Bölümü, İzmir, Türkiye
3. Ankara Yıldırım Beyazıt Üniversitesi Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Ankara, Türkiye
4. Aydın Adnan Menderes Üniversitesi Tıp Fakültesi, Biyokimya Anabilim Dalı, Aydın, Türkiye
No information available.
No information available
Received Date: 31.05.2023
Accepted Date: 04.02.2024
Publish Date: 27.03.2024



Axial spondyloarthritis is a chronic inflammatory disease primarily affecting the axial skeleton and the sacroiliac joints. In this study, we aimed to assess irisin levels in patients with ankylosing spondylitis (AS), compare them with healthy individuals, and explore the relationship between this adipomiyokine and activity, function, and structural damage in AS.


Ninety-seven patients classified as AS according to the modified New York criteria and 48 healthy controls were consecutively enrolled in the study. Serum irisin, interleukin (IL) 6, and high-sensitivity C-reactive protein (hs-CRP) measurements were performed using the ELISA method. Disease activity, functional assessments, and spinal radiographic scoring were conducted. The relationship between laboratory parameters, disease activation, and radiological parameters was evaluated using the Spearman correlation test.


The age and gender distributions of AS and controls were found to be similar. Smoking was significantly higher in the AS group (p=0.004). No significant difference in serum irisin levels was observed between AS and controls [100.0 (65.9) versus 103.0 (45.5), p=0.997]. However, serum IL-6, hs-CRP, and erythrocyte sedimentation rate averages were significantly higher in the patient group. There was no significant correlation between serum irisin levels in the AS group and inflammatory markers, Bath Ankylosing Spondylitis Functional index, Bath Ankylosing Spondylitis Disease Activity index, and Ankylosing Spondylitis Disease Activity score CRP scores, while a low to moderate correlation was found with the mSASS score (r: 0.362, p=0.005).


In this study, we did not find a significant difference in serum irisin levels between healthy controls and AS patients, nor did we observe a significant connection between irisin levels and disease activity.

Keywords: Ankylosing spondylitis, irisin, myokine


Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017;390:73-84.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
Ellinghaus D, Jostins L, Spain SL, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet 2016;48:510-8.
International Genetics of Ankylosing Spondylitis Consortium (IGAS); Cortes A, Hadler J, Pointon JP, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 2013;45:730-8.
Schett G, Lories RJ, D’Agostino MA, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 2017;13:731-41.
Packham J. Optimizing outcomes for ankylosing spondylitis and axial spondyloarthritis patients: a holistic approach to care. Rheumatology (Oxford) 2018;57(Suppl 6):vi29-34.
Moltó A, Nikiphorou E. Comorbidities in Spondyloarthritis. Front Med (Lausanne) 2018;5:62.
Papagoras C, Voulgari PV, Drosos AA. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 2013;31:612-20.
Liu S, Cui F, Ning K, et al. Role of irisin in physiology and pathology. Front Endocrinol (Lausanne) 2022;13:962968.
Sanchis-Gomar F, Perez-Quilis C. Irisinemia: a novel concept to coin in clinical medicine? Ann Nutr Metab 2013;63:60-1.
Choi YK, Kim MK, Bae KH, et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013;100:96-101.
Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013;98:E769-78.
Boström P, Wu J, Jedrychowski M, et al. A PGC1-a-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012;481:463-8.
Fu J, Li F, Tang Y, et al. The Emerging Role of Irisin in Cardiovascular Diseases. J Am Heart Assoc 2021;10:e022453.
Ou-Yang WL, Guo B, Xu F, et al. The Controversial Role of Irisin in Clinical Management of Coronary Heart Disease. Front Endocrinol (Lausanne) 2021;12:678309.
Askin L, Uzel KE, Tanriverdi O, Turkmen S. Serum Irisin: Pathogenesis and Clinical Research in Cardiovascular Diseases. Cardiovasc Innov Appl 2020;4:195-200.
Giardullo L, Corrado A, Maruotti N, Cici D, Mansueto N, Cantatore FP. Adipokine role in physiopathology of inflammatory and degenerative musculoskeletal diseases. Int J Immunopathol Pharmacol 2021;35:20587384211015034.
Raafat Ibrahim R, Shafik NM, El-Esawy RO, et al. The emerging role of irisin in experimentally induced arthritis: a recent update involving HMGB1/MCP1/Chitotriosidase I-mediated necroptosis. Redox Rep 2022;27:21-31.
Zheng G, Li H, Zhang T, et al. Irisin protects macrophages from oxidized low density lipoprotein-induced apoptosis by inhibiting the endoplasmic reticulum stress pathway. Saudi J Biol Sci 2018;25:849-57.
Li H, Wang F, Yang M, Sun J, Zhao Y, Tang D. The Effect of Irisin as a Metabolic Regulator and Its Therapeutic Potential for Obesity. Int J Endocrinol 2021;2021:6572342.
Nam B, Jo S, Lee S, Kim TH. AB0116 Decreased Serum Level of Irisin in Patients With Ankylosing Spondylitis. Ann Rheum Dis 2020;79:1358.
Remuzgo-Martínez S, Rueda-Gotor J, Pulito-Cueto V, et al. Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis. Front Immunol 2022;13:894171.
Wen MS, Wang CY, Lin SL, Hung KC. Decrease in irisin in patients with chronic kidney disease. PLoS One 2013;8:e64025.
Toussirot E. The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights. Front Med (Lausanne) 2021;8:782150.
Akad K, Solmaz D, Sari I, et al. Performance of response scales of activity and functional measures of ankylosing spondylitis: numerical rating scale versus visual analog scale. Rheumatol Int 2013;33:2617-23.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
van der Heijde D, Lie E, Kvien TK, et al. Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-8.
Creemers MC, Franssen MJ, van’t Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-9.
Silva J, Santo RCDE, Freitas E, et al. THU0080 Serum irisin and myostatin levels in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases 2018;77:263.
Soliman SA, Gad R, Senosy T, Higazi AM, Elshereef E. Serum irisin level in rheumatoid arthritis patients: relationship to disease activity, subclinical atherosclerosis, and cardiovascular risk factors. Egypt Rheumatologist 2022;44:109-14.
Cacciapuoti S, Scala E, Luciano MA, et al. Irisin, a novel metabolic biomarker in hidradenitis suppurativa: correlation with clinical responsivity to anti-TNF-a therapy. Ital J Dermatol Venerol 2023;158:124-7.
2024 ©️ Galenos Publishing House